A post on in-pharmatechnologist.com summarizes a report by Moody’s forecasting that pharmaceutical companies in the United States and Europe will face difficult times over the course of the next 12-18 months.

Some of the causes identified by Moody’s include:

  • patent expirations and challenges to existing patents;
  • difficult regulatory climate;
  • downward pricing pressures; and
  • unexpected problems related to product safety.